Abstract 982P
Background
Transarterial chemoembolization (TACE) is a treatment option for hepatocellular carcinoma (HCC), but the optional agent for TACE is limited. We compared the efficacy and safety of TACE with idarubicin versus epirubicin in HCC patients.
Methods
This is a non inferiority randomized controlled trial registered in clinicaltrials.gov with NCT05053386. 186 patients was needed according to calculation. Patients with liver-confined HCC, Eastern Cooperative Oncology Group (ECOG) score 0-1, Child-Pugh class A/B, and Barcelona Clinic Liver Cancer (BCLC) Stage A-C were randomly assigned in a 1:1 ratio to receive TACE with 10mg idarubicin (experimental group) or 50mg epirubicin (control group). The primary endpoint was objective response rate (ORR). The secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety.
Results
110 patients were recruited from October 2021 to April 2023 at 14 centers in China and randomly assigned to undergo TACE with idarubicin (n=55) or epirubicin (n=55). The median age was 63 years (range 35, 79), most were male (83.6%), ECOG score 0 (85.5%), Child-Pugh A (90.9%), hepatitis B (81.8%), there were no significant differences between groups in baseline characteristics (p>0.05). The experimental group has a good tumor response, as shown by higher ORR ( 66.0% vs 59.5%, p=0.530) and DCR (89.4% vs 81.0%, p=0.262) versus control group. The median PFS and median OS were not observed yet. No significant differences were found between groups in postembolization syndrome and liver toxicity (p>0.05). The incidence of thrombocytopenia was higher in control group than in experimental group (9.8% vs 25.0%, p=0.046). Grade 3 or 4 adverse events mainly included increased ALT/AST (ALT, 14.8% vs 22.2%, p=0.350; AST, 23.0% vs 19.4%, p=0.686).
Conclusions
Our interim results suggest that idarubicin could be a safe and effective treatment option for lipiodol TACE of HCC. This trial will progress as planned.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1000P - Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC)
Presenter: Daniel Ahn
Session: Poster session 18
1001P - Patients’ prioritization of treatment goals in hepatocellular carcinoma (HCC): A global qualitative observational study (PERIDOT)
Presenter: Marcus-Alexander Wörns
Session: Poster session 18
1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma
Presenter: Kai Tan
Session: Poster session 18
1003P - Efficacy and safety of triple combination therapy with transarterial chemoembolization (TACE), tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) versus dual combination therapy in unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis
Presenter: Omar Maaño
Session: Poster session 18
1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study
Presenter: Danjun Song
Session: Poster session 18
1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden
Presenter: Jiliang Qiu
Session: Poster session 18
1006P - Associations of online search trends and prescription trends for hepatocellular carcinoma drugs
Presenter: Philipp Berning
Session: Poster session 18
1007P - Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Presenter: David Trueman
Session: Poster session 18